Vascular and extravascular volume expansion of dobutamine and norepinephrine in normovolemic sheep

Christopher T. Stephens, Nabeel Uwaydah, George Kramer, Donald Prough, Michael Salter, Michael Kinsky

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In low-flow states, such as circulatory shock, both fluids and catecholamines are often coadministered. We have previously found that adrenergic agents alter volume expansion after a fluid bolus. The present study tested the volume expansion properties of dobutamine and norepinephrine in sheep treated with (series 1) and without (series 2) a fluid bolus. Series 1 (n = 6 per group): no drug (control), dobutamine (10 μg • kg -1 • min -1), or norepinephrine (1.0 μg • kg -1 • min -1) was begun 30 min before a 24-mL • kg -1, 20-min, 0.9% NaCl bolus. The effect of drug and fluid on plasma volume (ΔPV), urinary output (UOP), and extravascular volume (ΔEVV) was determined. Series 2: Identical protocol but no fluid bolus. Series 1: the fluid bolus resulted in a peak and sustained ΔPV expansion. Norepinephrine (7.5 ± 0.9 mL • kg -1) and dobutamine (9.5 ± 1.1 mL • kg -1) significantly increased ΔPV compared with control (3.8 ± 1.1 mL • kg -1). Cumulative UOP was reduced by dobutamine (3.8 ± 1.4 mL • kg -1) compared with norepinephrine (25.1 ± 3.9 mL • kg -1) and control (16.9 ± 4.0 mL • kg -1). Norepinephrine increased ΔPV, while reducing ΔEVV after bolus. Series 2: ΔPV was unchanged in the control group. Dobutamine and norepinephrine increased ΔPV over time, 5.1 ± 0.5 and 4.0 ± 0.5 mL • kg -1, respectively. At study end, UOP was lowest in dobutamine. Norepinephrine resulted in loss of ΔEVV fluid. data suggest a novel role for adrenergic receptors in regulating vascular and EVV expansion. β-Adrenergic agonists enhance vascular volume expansion, whereas α-adrenergic agonists eliminate extravascular fluid.

Original languageEnglish (US)
Pages (from-to)303-311
Number of pages9
JournalShock
Volume36
Issue number3
DOIs
StatePublished - Sep 2011

Fingerprint

Dobutamine
Plasma Volume
Blood Vessels
Sheep
Norepinephrine
Adrenergic Agonists
Drug and Narcotic Control
Adrenergic Agents
Adrenergic Receptors
Catecholamines
Shock
Control Groups
Pharmaceutical Preparations

Keywords

  • adrenergic agonists
  • catecholamine infusions
  • dobutamine
  • Fluid therapy
  • norepinephrine
  • sheep
  • vascular volume expansion

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine
  • Emergency Medicine

Cite this

Vascular and extravascular volume expansion of dobutamine and norepinephrine in normovolemic sheep. / Stephens, Christopher T.; Uwaydah, Nabeel; Kramer, George; Prough, Donald; Salter, Michael; Kinsky, Michael.

In: Shock, Vol. 36, No. 3, 09.2011, p. 303-311.

Research output: Contribution to journalArticle

Stephens, Christopher T. ; Uwaydah, Nabeel ; Kramer, George ; Prough, Donald ; Salter, Michael ; Kinsky, Michael. / Vascular and extravascular volume expansion of dobutamine and norepinephrine in normovolemic sheep. In: Shock. 2011 ; Vol. 36, No. 3. pp. 303-311.
@article{cb5ea6b6e24f4d5ebe020ebc4680d17a,
title = "Vascular and extravascular volume expansion of dobutamine and norepinephrine in normovolemic sheep",
abstract = "In low-flow states, such as circulatory shock, both fluids and catecholamines are often coadministered. We have previously found that adrenergic agents alter volume expansion after a fluid bolus. The present study tested the volume expansion properties of dobutamine and norepinephrine in sheep treated with (series 1) and without (series 2) a fluid bolus. Series 1 (n = 6 per group): no drug (control), dobutamine (10 μg • kg -1 • min -1), or norepinephrine (1.0 μg • kg -1 • min -1) was begun 30 min before a 24-mL • kg -1, 20-min, 0.9{\%} NaCl bolus. The effect of drug and fluid on plasma volume (ΔPV), urinary output (UOP), and extravascular volume (ΔEVV) was determined. Series 2: Identical protocol but no fluid bolus. Series 1: the fluid bolus resulted in a peak and sustained ΔPV expansion. Norepinephrine (7.5 ± 0.9 mL • kg -1) and dobutamine (9.5 ± 1.1 mL • kg -1) significantly increased ΔPV compared with control (3.8 ± 1.1 mL • kg -1). Cumulative UOP was reduced by dobutamine (3.8 ± 1.4 mL • kg -1) compared with norepinephrine (25.1 ± 3.9 mL • kg -1) and control (16.9 ± 4.0 mL • kg -1). Norepinephrine increased ΔPV, while reducing ΔEVV after bolus. Series 2: ΔPV was unchanged in the control group. Dobutamine and norepinephrine increased ΔPV over time, 5.1 ± 0.5 and 4.0 ± 0.5 mL • kg -1, respectively. At study end, UOP was lowest in dobutamine. Norepinephrine resulted in loss of ΔEVV fluid. data suggest a novel role for adrenergic receptors in regulating vascular and EVV expansion. β-Adrenergic agonists enhance vascular volume expansion, whereas α-adrenergic agonists eliminate extravascular fluid.",
keywords = "adrenergic agonists, catecholamine infusions, dobutamine, Fluid therapy, norepinephrine, sheep, vascular volume expansion",
author = "Stephens, {Christopher T.} and Nabeel Uwaydah and George Kramer and Donald Prough and Michael Salter and Michael Kinsky",
year = "2011",
month = "9",
doi = "10.1097/SHK.0b013e318225b031",
language = "English (US)",
volume = "36",
pages = "303--311",
journal = "Shock",
issn = "1073-2322",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Vascular and extravascular volume expansion of dobutamine and norepinephrine in normovolemic sheep

AU - Stephens, Christopher T.

AU - Uwaydah, Nabeel

AU - Kramer, George

AU - Prough, Donald

AU - Salter, Michael

AU - Kinsky, Michael

PY - 2011/9

Y1 - 2011/9

N2 - In low-flow states, such as circulatory shock, both fluids and catecholamines are often coadministered. We have previously found that adrenergic agents alter volume expansion after a fluid bolus. The present study tested the volume expansion properties of dobutamine and norepinephrine in sheep treated with (series 1) and without (series 2) a fluid bolus. Series 1 (n = 6 per group): no drug (control), dobutamine (10 μg • kg -1 • min -1), or norepinephrine (1.0 μg • kg -1 • min -1) was begun 30 min before a 24-mL • kg -1, 20-min, 0.9% NaCl bolus. The effect of drug and fluid on plasma volume (ΔPV), urinary output (UOP), and extravascular volume (ΔEVV) was determined. Series 2: Identical protocol but no fluid bolus. Series 1: the fluid bolus resulted in a peak and sustained ΔPV expansion. Norepinephrine (7.5 ± 0.9 mL • kg -1) and dobutamine (9.5 ± 1.1 mL • kg -1) significantly increased ΔPV compared with control (3.8 ± 1.1 mL • kg -1). Cumulative UOP was reduced by dobutamine (3.8 ± 1.4 mL • kg -1) compared with norepinephrine (25.1 ± 3.9 mL • kg -1) and control (16.9 ± 4.0 mL • kg -1). Norepinephrine increased ΔPV, while reducing ΔEVV after bolus. Series 2: ΔPV was unchanged in the control group. Dobutamine and norepinephrine increased ΔPV over time, 5.1 ± 0.5 and 4.0 ± 0.5 mL • kg -1, respectively. At study end, UOP was lowest in dobutamine. Norepinephrine resulted in loss of ΔEVV fluid. data suggest a novel role for adrenergic receptors in regulating vascular and EVV expansion. β-Adrenergic agonists enhance vascular volume expansion, whereas α-adrenergic agonists eliminate extravascular fluid.

AB - In low-flow states, such as circulatory shock, both fluids and catecholamines are often coadministered. We have previously found that adrenergic agents alter volume expansion after a fluid bolus. The present study tested the volume expansion properties of dobutamine and norepinephrine in sheep treated with (series 1) and without (series 2) a fluid bolus. Series 1 (n = 6 per group): no drug (control), dobutamine (10 μg • kg -1 • min -1), or norepinephrine (1.0 μg • kg -1 • min -1) was begun 30 min before a 24-mL • kg -1, 20-min, 0.9% NaCl bolus. The effect of drug and fluid on plasma volume (ΔPV), urinary output (UOP), and extravascular volume (ΔEVV) was determined. Series 2: Identical protocol but no fluid bolus. Series 1: the fluid bolus resulted in a peak and sustained ΔPV expansion. Norepinephrine (7.5 ± 0.9 mL • kg -1) and dobutamine (9.5 ± 1.1 mL • kg -1) significantly increased ΔPV compared with control (3.8 ± 1.1 mL • kg -1). Cumulative UOP was reduced by dobutamine (3.8 ± 1.4 mL • kg -1) compared with norepinephrine (25.1 ± 3.9 mL • kg -1) and control (16.9 ± 4.0 mL • kg -1). Norepinephrine increased ΔPV, while reducing ΔEVV after bolus. Series 2: ΔPV was unchanged in the control group. Dobutamine and norepinephrine increased ΔPV over time, 5.1 ± 0.5 and 4.0 ± 0.5 mL • kg -1, respectively. At study end, UOP was lowest in dobutamine. Norepinephrine resulted in loss of ΔEVV fluid. data suggest a novel role for adrenergic receptors in regulating vascular and EVV expansion. β-Adrenergic agonists enhance vascular volume expansion, whereas α-adrenergic agonists eliminate extravascular fluid.

KW - adrenergic agonists

KW - catecholamine infusions

KW - dobutamine

KW - Fluid therapy

KW - norepinephrine

KW - sheep

KW - vascular volume expansion

UR - http://www.scopus.com/inward/record.url?scp=80052023778&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052023778&partnerID=8YFLogxK

U2 - 10.1097/SHK.0b013e318225b031

DO - 10.1097/SHK.0b013e318225b031

M3 - Article

VL - 36

SP - 303

EP - 311

JO - Shock

JF - Shock

SN - 1073-2322

IS - 3

ER -